A. . Blauvelt, “Bimekizumab Continuous Maintenance of Eesponse at Every Visit Through Two Years in Patients with Moderate to Severe Plaque Psoriasis: Post-hoc Results from Five Phase 3/3b Trials”, J of Skin, vol. 8, no. 1, p. s303, Jan. 2024.